274 related articles for article (PubMed ID: 30975761)
21. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
22. DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
Erčulj N; Kovač V; Hmeljak J; Franko A; Dodič-Fikfak M; Dolžan V
J Thorac Oncol; 2012 Oct; 7(10):1609-17. PubMed ID: 22982660
[TBL] [Abstract][Full Text] [Related]
23. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
24. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
25. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
[TBL] [Abstract][Full Text] [Related]
26. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
Parrotta R; Okonska A; Ronner M; Weder W; Stahel R; Penengo L; Felley-Bosco E
J Thorac Oncol; 2017 Aug; 12(8):1309-1319. PubMed ID: 28389374
[TBL] [Abstract][Full Text] [Related]
27. Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
Lund-Andersen C; Nakken S; Nygård S; Fromm B; Aasheim LB; Davidson B; Julsrud L; Abrahamsen TW; Kristensen AT; Dybdahl B; Larsen SG; Hovig E; Flatmark K
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30862609
[TBL] [Abstract][Full Text] [Related]
28. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.
Ribeiro C; Campelos S; Moura CS; Machado JC; Justino A; Parente B
Ann Oncol; 2013 Aug; 24(8):2147-50. PubMed ID: 23585512
[TBL] [Abstract][Full Text] [Related]
29. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
Nasu M; Emi M; Pastorino S; Tanji M; Powers A; Luk H; Baumann F; Zhang YA; Gazdar A; Kanodia S; Tiirikainen M; Flores E; Gaudino G; Becich MJ; Pass HI; Yang H; Carbone M
J Thorac Oncol; 2015 Apr; 10(4):565-76. PubMed ID: 25658628
[TBL] [Abstract][Full Text] [Related]
30. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
31. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.
Betti M; Casalone E; Ferrante D; Romanelli A; Grosso F; Guarrera S; Righi L; Vatrano S; Pelosi G; Libener R; Mirabelli D; Boldorini R; Casadio C; Papotti M; Matullo G; Magnani C; Dianzani I
Genes Chromosomes Cancer; 2015 Jan; 54(1):51-62. PubMed ID: 25231345
[TBL] [Abstract][Full Text] [Related]
32. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A
Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
Zauderer MG; Jayakumaran G; DuBoff M; Zhang L; Francis JH; Abramson DH; Cercek A; Nash GM; Shoushtari A; Chapman P; D'Angelo S; Arnold AG; Siegel B; Fleischut MH; Ni A; Rimner A; Rusch VW; Adusumilli PS; Travis W; Sauter JL; Zehir A; Mandelker D; Ladanyi M; Robson M
J Thorac Oncol; 2019 Nov; 14(11):1989-1994. PubMed ID: 31323388
[TBL] [Abstract][Full Text] [Related]
34. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.
Kittaneh M; Berkelhammer C
J Transl Med; 2018 Jul; 16(1):194. PubMed ID: 30001711
[TBL] [Abstract][Full Text] [Related]
35. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
36. Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes.
Lau B; Kumar S; Yan T; Burn J; Kennedy C; McLean J; Boyer M; McCaughan B; Kao S
Lung Cancer; 2017 Sep; 111():75-78. PubMed ID: 28838403
[TBL] [Abstract][Full Text] [Related]
37. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
[TBL] [Abstract][Full Text] [Related]
38. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.
Cheung M; Talarchek J; Schindeler K; Saraiva E; Penney LS; Ludman M; Testa JR
Cancer Genet; 2013 May; 206(5):206-10. PubMed ID: 23849051
[TBL] [Abstract][Full Text] [Related]
39. Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
Hamasaki M; Matsumoto S; Abe S; Hamatake D; Kamei T; Hiroshima K; Kawahara K; Sato A; Tsujimura T; Nakatani Y; Yoshida Y; Iwasaki A; Nabeshima K
Lung Cancer; 2016 Sep; 99():155-61. PubMed ID: 27565933
[TBL] [Abstract][Full Text] [Related]
40. The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
Chou A; Toon CW; Clarkson A; Sheen A; Sioson L; Gill AJ
Histopathology; 2018 Feb; 72(3):509-515. PubMed ID: 28889523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]